drugset / Trial / NCT03203447
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO
RandomizedParallel-groupTriple-blindTreatment
Summary
This Phase 3, multicenter, randomized, masked, controlled, parallel group study is designed to demonstrate that suprachoroidal (SC) CLS-TA administered with intravitreal (IVT) anti-VEGF agent in subjects with treatment naive RVO is superior to IVT anti-VEGF agent used alone.
Timeline
- Start
- 2018-03-05
- Primary completion
- 2018-12-18
- Completion
- 2018-12-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | 1.25 mg | Intravitreal |
| Comparator | CLS-TA | Unknown | 4 mg | Other |
| Comparator | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |